Pharmabiz

Orca Bio’s Orca-Q receives US FDA’s RMAT designation for treatment of high-risk hematologic malignancies

Orca Bio’s Orca-Q receives US FDA’s RMAT designation for treatment of high-risk hematologic malignancies: Menlo Park, California Orca ...
Pharmabiz

Leaps by Bayer and BCG: New study highlights societal optimism toward breakthrough science, and rising anxiety about how fast the world is changing

New study highlights societal optimism toward breakthrough science, and rising anxiety about how fast the world is changing: Berlin Thursday, April 30, 202 ...
Pharmabiz

Vensica Medical receives US FDA IND clearance to begin phase 2 study of ViXe; a needle-free Xeomin delivery system for overactive bladder

Vensica Medical receives US FDA IND clearance to begin phase 2 study of ViXe; a needle-free Xeomin delivery system for overactive bladder: New York Thursday, April 30, 2026, 17:00 ...
Pharmabiz

National IPR conference at MIPS bridges gap between pharma research and industrial innovation

National IPR conference at MIPS bridges gap between pharma research and industrial innovation: Our Bureau, Chennai Thursday, ...
Pharmabiz

US FDA grants priority review to BeOne Medicines’ sBLA for Tevimbra in first-line HER2+ GEA

US FDA grants priority review to BeOne Medicines’ sBLA for Tevimbra in first-line HER2+ GEA: San Carlos, California Thursday, April 30, 2026, 16:00 Hrs [IST] BeOne Medicines Ltd ...
Pharmabiz

NHPC organises Heart Health Talk and Awareness Camp in association with Heartnet India

NHPC organises Heart Health Talk and Awareness Camp in association with Heartnet India: Our Bureau, Mumbai Thursday, April 30 ...
Pharmabiz

Lilly supports Haryana State-FDA action on counterfeits, reiterates sourcing via authorised channels on valid prescription

Lilly supports Haryana State-FDA action on counterfeits, reiterates sourcing via authorised channels on valid prescription: ...
Pharmabiz

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma

Pfizer announces positive results from phase 3 MagnetisMM-5 study of Elrexfio as monotherapy in adults with relapsed or refractory multiple myeloma: New York Thursday, April 30, 2 ...